DCM
ALNY icon

Davis Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Davis Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$602 Buy
2
+1
+100% +$302 ﹤0.01% 582
2026
Q1 		$331 Hold
1
– – ﹤0.01% 477
2025
Q4 		$398 Hold
1
– – ﹤0.01% 449
2025
Q3 		$456 Buy
+1
New +$407 ﹤0.01% 418

Other funds holding ALNY

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SSA
Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
OIAM
OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Davis Capital Management's ALNY Position: Q2 2026 in Review

Davis Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 100% in Q2 2026, buying an estimated $302 and bringing the position to 2 shares worth $602. The position accounts for ﹤0.01% of the portfolio, ranked #582.

Davis Capital Management first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. 149 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Davis Capital Management held 2 shares of Alnylam Pharmaceuticals worth $602 as of Q2 2026.
  • Davis Capital Management bought 1 Alnylam Pharmaceuticals share in Q2 2026, an estimated $302.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #582 holding.
  • Davis Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 149 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.